LLL12b treatment also increases the sensitivity of CD4+ T cells from MS patients to Treg-mediated suppression, suggesting that LLL12b has the potential to restore Teff:Treg balance of CD4+ T cells in MS patients. Here, CD4 is linked to myeloid sarcoma.